A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C

Trial Profile

A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Atherosclerosis; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ORION; ORION-1
  • Sponsors The Medicines Company
  • Most Recent Events

    • 09 Aug 2017 One-year follow-up data from this trial will be presented at the European Society of Cardiology (ESC) Congress 2017, according to The Medicines Company media release.
    • 03 Aug 2017 This trial has been completed in Netherlands (End date:2017-06-07) as per European Clinical Trials Database record.
    • 03 Aug 2017 Last checked against European Clinical Trials Database record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top